HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Figures and Tables All Versions of this Article: 296/6/C1248    most recent 00104.2009v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Google Scholar Articles by Sartori, R. Articles by Sandri, M. PubMed PubMed Citation Articles by Sartori, R. Articles by Sandri, M.

MUSCLE CELL BIOLOGY AND CELL MOTILITY

Smad2 and 3 transcription factors control muscle mass in adulthood

¹Venetian Institute of Molecular Medicine, Padova, Italy; ²Dulbecco Telethon Institute, Padova, Italy; and ³Department of Biomedical Sciences, University of Padova, Padova, Italy

Submitted 6 March 2009 ; accepted in final form 4 April 2009

Loss of muscle mass occurs in a variety of diseases, including cancer, chronic heart failure, aquired immunodeficiency syndrome, diabetes, and renal failure, often aggravating pathological progression. Preventing muscle wasting by promoting muscle growth has been proposed as a possible therapeutic approach. Myostatin is an important negative modulator of muscle growth during myogenesis, and myostatin inhibitors are attractive drug targets. However, the role of the myostatin pathway in adulthood and the transcription factors involved in the signaling are unclear. Moreover, recent results confirm that other transforming growth factor-β (TGF-β) members control muscle mass. Using genetic tools, we perturbed this pathway in adult myofibers, in vivo, to characterize the downstream targets and their ability to control muscle mass. Smad2 and Smad3 are the transcription factors downstream of myostatin/TGF-β and induce an atrophy program that is muscle RING-finger protein 1 (MuRF1) independent. Furthermore, Smad2/3 inhibition promotes muscle hypertrophy independent of satellite cells but partially dependent of mammalian target of rapamycin (mTOR) signaling. Thus myostatin and Akt pathways cross-talk at different levels. These findings point to myostatin inhibitors as good drugs to promote muscle growth during rehabilitation, especially when they are combined with IGF-1-Akt activators.

muscle atrophy; hypertrophy; Akt; myostatin

This article has been cited by other articles:

				M. R. Morissette, S. A. Cook, C. Buranasombati, M. A. Rosenberg, and A. Rosenzweig Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt Am J Physiol Cell Physiol, November 1, 2009; 297(5): 1124 - 1132. [Abstract] [Full Text] [PDF]

				S. Welle, K. Burgess, C. A. Thornton, and R. Tawil Relation between extent of myostatin depletion and muscle growth in mature mice Am J Physiol Endocrinol Metab, October 1, 2009; 297(4): E935 - E940. [Abstract] [Full Text] [PDF]

				S. Welle, A. Cardillo, M. Zanche, and R. Tawil Skeletal muscle gene expression after myostatin knockout in mature mice Physiol Genomics, August 7, 2009; 38(3): 342 - 350. [Abstract] [Full Text] [PDF]

				A. U. Trendelenburg, A. Meyer, D. Rohner, J. Boyle, S. Hatakeyama, and D. J. Glass Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size Am J Physiol Cell Physiol, June 1, 2009; 296(6): C1258 - C1270. [Abstract] [Full Text] [PDF]

				S. L. Welle Myostatin and muscle fiber size. Focus on "Smad2 and 3 transcription factors control muscle mass in adulthood" and "Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size" Am J Physiol Cell Physiol, June 1, 2009; 296(6): C1245 - C1247. [Full Text] [PDF]